Skip to main content
. 2021 Jun 16;2021:8837825. doi: 10.1155/2021/8837825

Figure 1.

Figure 1

The serum CCL24 in patients with early DN is significantly increased compared with diabetic patients. (a–f) Serum inflammation antibody chip screening results in patients with diabetes and early DN. (g, h) Fluorescence intensity and statistical results of serum CCL24 inflammatory antibody chip in patients with diabetes mellitus and early and DN. n ≥ 3, p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. DN: patients with diabetic nephropathy, DM: diabetes patients without DN.